Results 151 to 160 of about 49,837 (289)

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 12, Page 3173-3194, June 2026.
Cannabidiol (CBD) and cannabigerol (CBG) alleviate hepatic steatosis in obese mice by shifting energy buffering towards phosphocreatine and enhancing lysosomal lipid degradation and trafficking. These effects are associated with increased creatine kinase activity and lysobisphosphatidic acid (LBPA) levels, highlighting a previously unrecognised ...
Radka Kočvarová   +12 more
wiley   +1 more source

Labour induction and adverse perinatal outcomes: a retrospective cohort study. [PDF]

open access: yesBMC Pregnancy Childbirth
Héritier M   +5 more
europepmc   +1 more source

Discovery of a Plant Pictet–Spenglerase With R‐Stereoselectivity

open access: yesAngewandte Chemie, Volume 138, Issue 20, 11 May 2026.
Strictosidine synthases (STRs) are plant Pictet–Spenglerases catalyzing the coupling of a secoiridoid with tryptamine. All previously characterized strictosidine synthases are strictly S‐selective. Here, we report the discovery of Epi‐STR, an R‐selective STR ortholog from the medicinal plant Pogonopus speciosus.
Clara Morweiser   +3 more
wiley   +2 more sources

Correction: Intubation of obese patients in the operating room with or without bag-mask ventilation: study protocol for a randomized multicenter trial (VENT OR NOT). [PDF]

open access: yesTrials
Znaïdi S   +18 more
europepmc   +1 more source

New RHCE*cE allele with c.872C>G and variable RH3 and RH4 phenotypes, predicted to encode p.Pro291Arg

open access: yes
Transfusion, EarlyView.
Evelyne Heng   +5 more
wiley   +1 more source

SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4602-4609, June 2026.
ABSTRACT Background Although semaglutide 2.4 mg has demonstrated significant weight loss efficacy in clinical trials, real‐world data, particularly with regard to clinically complex and underrepresented populations, remain limited. Objectives The study aims to assess the real‐world effectiveness and patient‐reported outcomes associated with the use of ...
Pierre Bel Lassen   +20 more
wiley   +1 more source

United Kingdom Butterfly Monitoring Scheme annual report 2007 [PDF]

open access: yes, 2008
Botham, M. S.   +4 more
core  

Home - About - Disclaimer - Privacy